logo

Lipocine Inc (LPCN)



Trade LPCN now with
  Date
  Headline
10/11/2018 8:06:39 AM Lipocine Reports LPCN 1144 Clinical Trial Results Selected For Late-Breaker Presentation At The Liver Meeting 2018
8/7/2018 7:45:23 AM Lipocine Q2 Net Loss $3.3 Mln Or $0.15/Shr Vs Loss Of $6.1 Mln Or $0.31/Shr Last Year
6/7/2018 8:10:14 AM Lipocine Announces Dosing In Ambulatory Blood Pressure Study For TLANDO
5/9/2018 7:00:31 AM Lipocine Receives Complete Response Letter From FDA For TLANDO
5/7/2018 8:12:17 AM Lipocine Q1 Net Loss Of $2.7 Mln Or $0.13/shr Vs. Net Loss Of $4.9 Mln Or $0.26/shr Prior Year
3/12/2018 8:11:08 AM Lipocine FY Net Loss $21.0 Mln Or $1.05/Shr Vs Loss Of $19.0 Mln Or $1.04/Shr Last Year
1/11/2018 10:33:06 AM Canaccord Is Increasing Lipocine Inc (LPCN) FY18 Estimate To -1.05 From -1.10
1/11/2018 10:24:34 AM Canaccord Lowers Lipocine Inc (LPCN) To Hold From Buy With $2 Down From $11 Price Target
11/17/2017 8:06:47 AM Lipocine Says FDA Extended Review Period For NDA For TLANDO
11/8/2017 8:12:56 AM Lipocine Q3 Net Loss $4.7 Mln Or $0.22/shr Vs. Loss Of $3.2 Mln Or $0.18/shr Prior Year